Majority of NSCLC patients are diagnosed with advanced disease1

Incidence, mortality, and survival for non-small cell lung cancer

INDICATION

ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

Majority of NSCLC patients are diagnosed with advanced disease1

Incidence, mortality, and survival for non-small cell lung cancer
aTotal metastatic incidence includes newly diagnosed and newly recurrent.
Incidence, mortality, and survival for non-small cell lung cancer

INDICATION

ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

INDICATION

ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.